Evidence map›Paper›PMID 23265346›Full record

Trial reportJournal of the American College of Cardiology2013

Low-dose colchicine for secondary prevention of cardiovascular disease.

Stefan M Nidorf, John W Eikelboom, Charley A Budgeon, Peter L Thompson

7 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 442 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
442citing papers in PubMed, 11 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04056039 phase2completedstarted 2018, after this paper: background citation

Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.

Ran2018Enrolled60Registered outcomes3Posted comparisons0ConditionsArthritis, Rheumatoid, Cardiovascular DiseasesArmsAtorvastatin, Colchicine
PMID 27580061PMID 25533796PMID 25662717PMID 24820145PMID 24720919PMID 20053272PMID 24093840PMID 18926169PMID 22986289PMID 16972704PMID 15189396PMID 11358070other papers from this trial
Open the trial in the graph
NCT02035891 naunknown statusnot on this map

Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study

TypeinterventionalSponsorChongqing Medical UniversityRan2013 to 2023Enrolled160ConditionsDiabetic NephropathyArmscolchicine 0.5mg/d, placebo 0.5mg/d
NCT02366091 phase2completednot on this mapstarted 2015, after this paper: background citation

Inflammation and Coronary Endothelial Function in Patients With Coronary Artery Disease

TypeinterventionalSponsorJohns Hopkins UniversityRan2015 to 2020Enrolled111ConditionsCoronary Artery DiseaseArmsMethotrexate, Colchicine, Placebo
NCT02624180 phase2completednot on this mapstarted 2015, after this paper: background citation

Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

TypeinterventionalSponsorJohns Hopkins UniversityRan2015 to 2020Enrolled81ConditionsCoronary Artery Disease, Human Immunodeficiency VirusArmsColchicine, Placebo
NCT04181996 phase3completednot on this mapstarted 2020, after this paper: background citation

The Canadian Study of Arterial Inflammation in Patients With Diabetes and Recent Vascular Events: EvaluatioN of Colchicine Effectiveness (CADENCE)

TypeinterventionalSponsorOttawa Heart Institute Research CorporationRan2020 to 2025Enrolled115ConditionsCardiovascular Diseases, Atherosclerosis, Inflammation, DiabetesArmsColchicine Oral Product, Placebo oral capsule
NCT05956145 nacompletednot on this mapstarted 2021, after this paper: background citation

Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease

TypeinterventionalSponsorUniversity of Sao PauloRan2021 to 2024Enrolled80ConditionsPlatelet Aggregation, Spontaneous, Coronary Artery DiseaseArmsColchicine 0.5 MG, Placebo
NCT06095765 phase3recruitingnot on this mapstarted 2024, after this paper: background citation

Colchicine in Belgium in Patients With Coronary Artery Disease

TypeinterventionalSponsorAZ Sint-Jan AVRan2024 to 2028Enrolled2,770ConditionsCoronary Artery DiseaseArmsColchicine 0.5 MG Oral Tablet, Placebo
3 · Its place in the literature

Who cites it

442 citing papers in PubMed, 11 syntheses or guidelines pooled it, 1,018 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025
    Pooled it
  8. Efficacy of Colchicine for Prevention of Stroke and Adverse Cardiovascular Events: A Meta-analysis of 16 Randomized Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

382 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Stefan M NidorfHeart Care Western Australia, Perth, Western Australia, Australia. Electronic address: smnidorf@gmail.com.
John W EikelboomMcMaster University, Hamilton, Ontario, Canada.
Charley A BudgeonCentre for Applied Statistics, University of Western Australia, Perth, Western Australia, Australia.
Peter L ThompsonHeart Research Institute of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Australian Centre for Heart Health · AUMcMaster University · CASir Charles Gairdner Hospital · AUThe University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascular events in patients with clinically stable coronary disease.

backgroundThe presence of activated neutrophils in culprit atherosclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition of neutrophil function with colchicine may reduce the risk of plaque instability and thereby improve clinical outcomes in patients with stable coronary disease.

methodsIn a clinical trial with a prospective, randomized, observer-blinded endpoint design, 532 patients with stable coronary disease receiving aspirin and/or clopidogrel (93%) and statins (95%) were randomly assigned colchicine 0.5 mg/day or no colchicine and followed for a median of 3 years. The primary outcome was the composite incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke. The primary analysis was by intention-to-treat.

resultsThe primary outcome occurred in 15 of 282 patients (5.3%) who received colchicine and 40 of 250 patients (16.0%) assigned no colchicine (hazard ratio: 0.33; 95% confidence interval [CI] 0.18 to 0.59; p < 0.001; number needed to treat: 11). In a pre-specified secondary on-treatment analysis that excluded 32 patients (11%) assigned to colchicine who withdrew within 30 days due to intestinal intolerance and a further 7 patients (2%) who did not start treatment, the primary outcome occurred in 4.5% versus 16.0% (hazard ratio: 0.29; 95% CI: 0.15 to 0.56; p < 0.001).

conclusionsColchicine 0.5 mg/day administered in addition to statins and other standard secondary prevention therapies appeared effective for the prevention of cardiovascular events in patients with stable coronary disease.

Indexed as

Acute Coronary SyndromeBrain InfarctionColchicineCoronary DiseaseOut-of-Hospital Cardiac ArrestPlaque, AtheroscleroticAgedCanadaDrug Therapy, CombinationEndpoint DeterminationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceIntestinal DiseasesMaleColchicineHydroxymethylglutaryl-CoA Reductase InhibitorsTubulin Modulators

Identifiers

PMID23265346
OpenAlexW2113978145

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.